Combining liraglutide, a GLP-1 peptide drug, with phosphatidylcholine therapy boosted clinical effectiveness from 83% to 95% in patients with nonalcoholic fatty liver disease.
95% vs 83%clinical effectiveness rate with combination liraglutide therapy versus standard treatment alone for fatty liver disease
What the researchers found
Combining polyene phosphatidylcholine (PPC) with the GLP-1 peptide agonist liraglutide achieved a 95% clinical effectiveness rate in NAFLD patients versus 83.33% for PPC alone. The combination therapy produced significantly greater reductions in liver enzymes (ALT, AST, GGT), vaspin, and FGF21, along with greater increases in the beneficial adipokine omentin-1.
Why it matters
NAFLD is one of the most common liver diseases worldwide. This study demonstrates that adding the peptide drug liraglutide to standard phospholipid therapy significantly improves outcomes, suggesting a role for GLP-1 receptor agonists beyond their well-known metabolic benefits.
The numbers in context
n=120 · 95% vs 83.33% clinical effectiveness · 12-week treatment · p<0.05
How the study worked
Randomized controlled trial with 120 NAFLD patients split equally into two groups. The control group received PPC alone while the observation group received PPC plus liraglutide for 12 weeks. Researchers measured clinical effectiveness, liver enzymes, and adipokine levels before and after treatment.
Who was studied
120 adults with nonalcoholic fatty liver disease
What this study cannot tell us
Relatively small sample size of 120 patients. The 12-week treatment period may not capture long-term outcomes. The abstract does not detail randomization methods, blinding, or specific dosing. Published in a complementary/alternative medicine journal rather than a hepatology-focused journal.
How to read the evidence
This is a randomized controlled trial with 120 patients, which represents moderate-quality clinical evidence. However, details about blinding and randomization methodology are limited in the abstract, and the relatively small sample size limits generalizability.
When this study was published
Published in 2025, this is very recent research reflecting current clinical interest in GLP-1 peptide agonists for liver disease management.
The bigger picture
GLP-1 receptor agonists like liraglutide, originally developed for diabetes, are increasingly being studied for liver disease. This trial adds to growing evidence that these peptide drugs may benefit NAFLD patients beyond blood sugar control, particularly when combined with established liver-protective therapies. The adipokine improvements suggest mechanisms beyond simple weight loss.
Questions still open
- Would longer treatment with liraglutide produce even greater improvements in liver health markers?
- Do newer GLP-1 agonists like semaglutide show similar or superior benefits in combination therapy for NAFLD?
- Can the adipokine changes (omentin-1, vaspin) serve as reliable biomarkers for tracking NAFLD treatment response?
Common questions
What is liraglutide and how does it relate to peptide research?
What are omentin-1 and vaspin, and why do they matter in this study?
Read the original research
Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.
Alternative therapies in health and medicine, 31(4), 273-277
Citation
Jin, Yao; Liu, Tong; Tong, Zhiqiang; Dong, Mei. (2025). Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.. Alternative therapies in health and medicine, 31(4), 273-277.